A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Beckman Symposium Bookmark and Share

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego

Beckman Symposium

The 24th Beckman Symposium - New Horizons on Oncogenesis

Date
Friday, November 14, 2014
8:45 a.m. to 5:30 p.m.

Location
City of Hope
Cooper Auditorium
1500 E. Duarte Road
Duarte, CA 91010-3000

Overview
The 24th Beckman Symposium to be held at Beckman Research Institute of City of Hope. Supported by funds from the Beckman Endowment, the Beckman Symposia are arranged annually by the research staff organization of City of Hope.
 
 
2014 Speaker List:
 
Joe Gray, Ph.D.,
Knight Cancer Institute, University of Oregon Health and Science University
 
Edward T.H. Yeh, M.D.,
University of Texas MD Anderson Cancer Center
 
Iannis Aifantis, Ph.D.,
Howard Hughes Medical Institute and NYU School of Medicine
 
Valerie Weaver, Ph.D.,
University of California, San Francisco
 
Channing Der, Ph.D.,
Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
Dafna Bar-Sagi, Ph.D.,
NYU Langone Medical Center
 
David Cheresh, Ph.D.,
Moores Cancer Center, University of California,  San Diego

 

In compliance with the Americans with Disabilities Act, all reasonable efforts will be made to accommodate persons with disabilities at the meeting. If you have any special dietary or accommodation needs, please notify the program coordinator listed above prior to the symposium. This advance notification will help us serve you better.

 

Symposium Program

2014 Symposium Program

8:15 to 8:45 a.m.
Registration
 
8:50 to 9:00 a.m.
Welcome, Steven Rosen, M.D., Provost, City of Hope
 
9:00 to 10:00 a.m.
Spatial Systems Biology of Cancer
Joe Gray, Ph.D., Knight Cancer Institute, University of Oregon Health and Science University
 
10:00 to 10:15 a.m.
Break
 
10:15 to 11:15 a.m.
Doxorubicin-induced Cardiotoxicity: SUMO, Ubiquitin, and Topoisomerase 2b
Edward T.H. Yeh, M.D., University of Texas MD Anderson Cancer Center
 
11:15 a.m. to 12:15 p.m.
Epigenetic Regulation of Acute Leukemia Initiation and Progression Iannis Aifantis, Ph.D., Howard Hughes Medical Institute and NYU School of Medicine
 
12:15 to 1:15 p.m.
Lunch
 
1:15 to 2:15 p.m.
Tissue Force, Tumor Progression and Treatment
Valerie Weaver, Ph.D., University of California, San Francisco
 
2:15 to 3:15 p.m.
Drugging the Undruggable Ras: Mission Possible?
Channing Der, Ph.D., Lineberger Comprehensive Cancer Center,   University of North Carolina, Chapel Hill
 
3:15 to 3:30 p.m.
Break
 
3:30 to 4:30 p.m.
Oncogenic Ras Signaling: From Biology to Therapeutics
Dafna Bar-Sagi, Ph.D., NYU Langone Medical Center
 
4:30 to 5:30 p.m.
A β3 Integrin-KRAS-RalB Complex Drives Tumor Stemness and Resistance to EGFR Inhibition
David Cheresh, Ph.D., Moores Cancer Center, University of California,  San Diego
Research Overview
City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.

Beckman Research Institute

Beckman Research Institute of City of Hope is internationally  recognized for its innovative translational biomedical research.
 

Comprehensive Cancer Center
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and education.

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

Technology & Licensing
The Center for Applied Technology Development offers broad expertise in
technology transfer and licensing, biologics manufacturing, quality assurance and regulatory affairs.

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 



NEWS & UPDATES
  • Few clinical cancer trials include older adults – and yet, more than 60 percent of cancer cases in the United States occur in people age 65 and older. The result is a dearth of knowledge on how to treat the very population most likely to be diagnosed with cancer. Now, the American Society of Clinical […]
  • Scientists at City of Hope and UCLA have become the first to inhibit the expression of a protein, called TWIST that promotes tumor invasion and metastasis when activated by cancer cells. As such, they’ve taken the first step in developing a potential new therapy for some of the deadliest cancers, including ovar...
  • Upon completing her final round of chemotherapy for ovarian cancer earlier this month, Maria Velazquez-McIntyre, a 51-year-old Antelope Valley resident, celebrated the milestone by giving other patients a symbol of hope – a Survivor Bell. The bell may look ordinary, but for cancer patients undergoing chemothera...
  • Many Americans understand that obesity is tied to heart disease and diabetes but, according to a new survey, too few – only 7 percent – know that obesity increases the risk of cancer. Specific biological characteristics can increase cancer risk in obese people, and multiple studies have shown correlations betwe...
  • As breast cancer survivors know, the disease’s impact lingers in ways both big and small long after treatment has ended. A new study suggests that weight gain – and a possible corresponding increase in heart disease and diabetes risk – may be part of that impact. In the first study to evaluate weight chan...
  • Becoming what’s known as an independent scientific researcher is no small task, especially when working to translate research into meaningful health outcomes. Yet that independent status is vital, enabling researchers to lead studies and avenues of inquiry that they believe to be promising. Clinicians, especial...
  • 720 days. That’s how long Alex Tung, 38, had to give up surfing after being diagnosed with acute myeloid leukemia. For most people, even some surfers, such a hiatus wouldn’t be a big deal, but for Tung, surfing has been everything. The Southern California resident began surfing when he was in elemen...
  • There are few among us who have not experienced loss of a friend or loved one, often without warning, or like those of us who care for people with cancer, after a lingering illness. It is a time when emotions run high and deep, and as time passes from the moment of loss, we often […]
  • For the past four years, neurosurgeon and scientist Rahul Jandial, M.D., Ph.D., has been studying how breast cancer cells spread, or metastasize, to the brain, where they become life-threatening tumors. Known as secondary brain tumors, these cancers have become increasingly common as treatment advances have ena...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. A primary symptom is a rash that arises initially in areas of the skin that are not normally exposed to sunlight....
  • There’s science camp, and then there’s “mystery” science camp. City of Hope’s new science camp for middle school students is of the especially engaging latter variety. From Monday, July 13, to Friday, July 17, rising middle-school students from across the San Gabriel Valley were presented with a “patient” with ...
  • Women diagnosed with breast cancer quickly learn their tumor’s type, meaning the characteristics that fuel its growth. That label guides the treatment of their disease, as well as their prognosis when it comes to treatment effectiveness. Sometimes, however, doctors can’t accurately predict treatment effectivene...
  • In years past, Bladder Cancer Awareness Month has been a sobering reminder of a disease with few treatment options. For patients with metastatic disease (disease that has spread from the bladder to distant organs), average survival is typically just over one year. Fortunately, things are changing. Academic inst...
  • Tina Wang was diagnosed with Stage 4 diffuse large b cell lymphoma at age 22. She first sought treatment at her local hospital, undergoing two cycles of treatment. When the treatment failed to eradicate her cancer, she came to City of Hope. Here, Wang underwent an autologous stem cell transplant and participate...
  • When Gilbert Fresquez, 72, lost an excessive amount of weight in late 2012, he didn’t think much of it. He assumed it was a side effect from a recent surgery to remove a carcinoid tumor in his small intestine. It wasn’t until a couple of years later during a routine doctor’s visit that the retired […]